| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 21-08-03 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +7.19% | +2.67% | - | - | 148M | ||
| +1.10% | +1.56% | +16.18% | +80.60% | 48.17B | ||
| +0.36% | -5.82% | +64.42% | +114.68% | 35.47B | ||
| +0.80% | -2.32% | -3.16% | +40.89% | 12.04B | ||
| +0.20% | -1.25% | +15.72% | +91.66% | 11.79B | ||
| +0.75% | +1.53% | +33.50% | +127.47% | 9.15B | ||
| +1.09% | -2.20% | +17.94% | +38.04% | 6.91B | ||
| +1.33% | -0.65% | +50.85% | -4.70% | 6.95B | ||
| +0.17% | +1.51% | +5.69% | +237.37% | 6.79B | ||
| +3.56% | -8.79% | -19.28% | +11.24% | 5.77B | ||
| Average | +1.66% | -1.43% | +20.21% | +81.92% | 15.89B | |
| Weighted average by Cap. | +0.87% | -1.88% | +27.43% | +88.06% |
Employees
2,191
Sector
Pharmaceuticals
















